Research programme: AAV-based eye disorder gene therapies - 4D Molecular Therapeutics

Drug Profile

Research programme: AAV-based eye disorder gene therapies - 4D Molecular Therapeutics

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 4D Molecular Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Blindness

Most Recent Events

  • 01 Dec 2016 4D Molecular Therapeutics initiates an observational study for Choroideremia in USA for
  • 23 Feb 2016 Early research in Blindness in USA (Intravitreous)
  • 23 Feb 2016 4D Molecular Therapeutics and Choroideremia Research Foundation enter into collaboration to develop AAV-based gene therapy in USA for Choroideremia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top